Onkologie. 2019:13(2):69-72 | DOI: 10.36290/xon.2019.013
Immunotherapy for breast cancer
- Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
The treatment of breast cancer is comprehensive, involving all available modalities. Due to advances in therapeutic options, the prognosis has been improved in many patients. Recently, immunotherapy has been one of the major advances in the treatment options for tumour diseases. Checkpoint inhibitors have been employed in an ever-increasing group of solid tumour diseases, and their use is associated, for some diagnoses in particular, with a substantial improvement in treatment outcomes and patient prognosis. Currently, immunotherapy is used predominantly in treating malignant melanoma, renal carcinoma, lung cancer, head and neck cancer, and bladder cancer. In treating breast cancer, immunotherapy has not yet earned its place; however, results of clinical trials have been available, currently even for phase III trials, suggesting good efficacy of immunotherapy, particularly in HER2-positive and triple-negative breast cancers (TNBC).
Keywords: breast cancer, immunotherapy
Published: April 5, 2019 Show citation
References
- Loi S, Giobbie-Hurder A, Gombos A, et al. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive advanced breast cancer: results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014). Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, TX. Abstract GS2-06
Go to original source... - den Brok WD, Speers CH, Gondara L, et al. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat 2017;161: 549-56. Go to original source...
Go to PubMed... - Bonotto M, Gerratana L, Poletto E, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 2014; 19: 608-615. Go to original source... Go to PubMed...
- Gobbini E, Ezzalfani M, Dieras V, et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer 2018; 96: 17-24. Go to original source... Go to PubMed...
- Nanda R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. Journal of Clinical Oncology, 2016, 34(21): 2460-2467. Go to original source... Go to PubMed...
- Adams S, et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. 2017. Go to original source...
- Adams S, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. 2017. Go to original source...
- Schmid P, et al. Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017; 77(13 Suppl): Abstract nr 2986. doi:10.1158/1538-7445.AM2017-2986. Go to original source...
- Sylvia A JD, Hamilton E, Pohlmann P, et al. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 2016; 34.
- Schmid P, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 2018. Go to original source... Go to PubMed...